Clarity
Clarity Technologies is developing novel, non-invasive, light and sound stimulation-based therapeutics to address Alzheimer's disease and other neurological conditions. Their solution involves a sensory stimulation device and a companion platform, including a mobile app and healthcare platform, designed to personalize treatment protocols and improve patient journeys. The therapy aims to slow cognitive decline, improve memory, sleep, and quality of life, offering a safer, non-pharmacological alternative to traditional treatments. Clarity is currently focused on clinical trials to validate their approach, working with experts and partners in neuroscience and medicine. The company's mission is to improve human life by making brain health accessible from home and redefining how aging and neurological health are managed.
Clarity
Clarity Technologies is developing novel, non-invasive, light and sound stimulation-based therapeutics to address Alzheimer's disease and other neurological conditions. Their solution involves a sensory stimulation device and a companion platform, including a mobile app and healthcare platform, designed to personalize treatment protocols and improve patient journeys. The therapy aims to slow cognitive decline, improve memory, sleep, and quality of life, offering a safer, non-pharmacological alternative to traditional treatments. Clarity is currently focused on clinical trials to validate their approach, working with experts and partners in neuroscience and medicine. The company's mission is to improve human life by making brain health accessible from home and redefining how aging and neurological health are managed.
TL;DR
Stage: Clinical-stage
Product: Personalized VR/light-and-sound 40 Hz gamma stimulation headset (investigational)
Therapeutic focus: Alzheimer's disease and other neurodegenerative conditions
Founders / leadership: Raphael Certain (CEO), Carolina Reis, Ph.D (CSO)
Employees: 19
Company Overview
Problem Domain
Neurodegenerative disease treatment and at-home neuromodulation therapies (Alzheimer's disease, mild cognitive impairment, aging-related cognitive decline).
Industry
Neurotechnology / Digital Therapeutics
Funding Track Record
Investor Signal
“Clarity has reported investor support including Pareto Holdings and other named investors; specific funding rounds or amounts beyond the disclosed total of 0.00 USD are not included in the company snapshot evidence.”